As a proof-of-concept, we show that this metastatic breast cancer cell-of-origin signature can be synergistically targeted with HDAC and HSP90 inhibitors combined with Niclosamide in sixteen out of seventeen breast cancer cell lines. Here, HDAC9 is linked to breast cancer.